SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis
FRA:SRT3 - Deutsche Boerse Ag - DE0007165631 - Currency: EUR
Taking everything into account, SRT3 scores 3 out of 10 in our fundamental rating. SRT3 was compared to 18 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of SRT3 have multiple concerns. SRT3 is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SRT3 had positive earnings in the past year.
SRT3 had a positive operating cash flow in the past year.
Each year in the past 5 years SRT3 has been profitable.
Each year in the past 5 years SRT3 had a positive operating cash flow.
1.2 Ratios
SRT3's Return On Assets of 1.04% is on the low side compared to the rest of the industry. SRT3 is outperformed by 77.78% of its industry peers.
SRT3's Return On Equity of 3.92% is on the low side compared to the rest of the industry. SRT3 is outperformed by 72.22% of its industry peers.
SRT3 has a Return On Invested Capital of 3.80%. This is in the lower half of the industry: SRT3 underperforms 72.22% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SRT3 is in line with the industry average of 6.95%.
The 3 year average ROIC (8.34%) for SRT3 is well above the current ROIC(3.80%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.04% | ||
| ROE | 3.92% | ||
| ROIC | 3.8% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
1.3 Margins
With a Profit Margin value of 3.00%, SRT3 is not doing good in the industry: 72.22% of the companies in the same industry are doing better.
SRT3's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 12.48%, SRT3 is doing worse than 66.67% of the companies in the same industry.
In the last couple of years the Operating Margin of SRT3 has declined.
The Gross Margin of SRT3 (45.76%) is better than 72.22% of its industry peers.
In the last couple of years the Gross Margin of SRT3 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.48% | ||
| PM (TTM) | 3% | ||
| GM | 45.76% |
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
SRT3 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, SRT3 has more shares outstanding
SRT3 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SRT3 has been reduced compared to a year ago.
2.2 Solvency
SRT3 has an Altman-Z score of 1.99. This is not the best score and indicates that SRT3 is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of SRT3 (1.99) is worse than 61.11% of its industry peers.
The Debt to FCF ratio of SRT3 is 8.09, which is on the high side as it means it would take SRT3, 8.09 years of fcf income to pay off all of its debts.
SRT3 has a Debt to FCF ratio of 8.09. This is in the lower half of the industry: SRT3 underperforms 66.67% of its industry peers.
SRT3 has a Debt/Equity ratio of 1.54. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of SRT3 (1.54) is worse than 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.54 | ||
| Debt/FCF | 8.09 | ||
| Altman-Z | 1.99 |
ROIC/WACC0.55
WACC6.93%
2.3 Liquidity
A Current Ratio of 1.39 indicates that SRT3 should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.39, SRT3 is doing worse than 66.67% of the companies in the same industry.
SRT3 has a Quick Ratio of 1.39. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.88, SRT3 is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
SRT3 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.21%, which is quite impressive.
The earnings per share for SRT3 have been decreasing by -11.87% on average. This is quite bad
SRT3 shows a small growth in Revenue. In the last year, the Revenue has grown by 3.80%.
SRT3 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.10% yearly.
EPS 1Y (TTM)33.21%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%7.02%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%2.74%
3.2 Future
The Earnings Per Share is expected to grow by 19.27% on average over the next years. This is quite good.
SRT3 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.50% yearly.
EPS Next Y22.89%
EPS Next 2Y24.43%
EPS Next 3Y26.21%
EPS Next 5Y19.27%
Revenue Next Year5.64%
Revenue Next 2Y7.36%
Revenue Next 3Y8.73%
Revenue Next 5Y8.5%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 40.80, which means the current valuation is very expensive for SRT3.
SRT3's Price/Earnings ratio is rather expensive when compared to the industry. SRT3 is more expensive than 83.33% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.03, SRT3 is valued quite expensively.
SRT3 is valuated quite expensively with a Price/Forward Earnings ratio of 27.97.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRT3 indicates a slightly more expensive valuation: SRT3 is more expensive than 66.67% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.28, SRT3 is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.8 | ||
| Fwd PE | 27.97 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SRT3 is valued a bit more expensive than the industry average as 61.11% of the companies are valued more cheaply.
61.11% of the companies in the same industry are more expensive than SRT3, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.1 | ||
| EV/EBITDA | 19.99 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
SRT3's earnings are expected to grow with 26.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.78
PEG (5Y)N/A
EPS Next 2Y24.43%
EPS Next 3Y26.21%
5. Dividend
5.1 Amount
SRT3 has a yearly dividend return of 0.47%, which is pretty low.
The stock price of SRT3 dropped by -22.38% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
Compared to an average industry Dividend Yield of 0.73, SRT3 has a dividend in line with its industry peers.
With a Dividend Yield of 0.47, SRT3 pays less dividend than the S&P500 average, which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.47% |
5.2 History
The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
SRT3 pays out 48.70% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of SRT3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP48.7%
EPS Next 2Y24.43%
EPS Next 3Y26.21%
FRA:SRT3 (8/6/2025, 5:36:15 PM)
177.5
-0.8 (-0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners4.37%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.29B
Analysts77.14
Price Target356.2 (100.68%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.47% |
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP48.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.33%
Min EPS beat(2)-10.52%
Max EPS beat(2)-4.13%
EPS beat(4)0
Avg EPS beat(4)-10.28%
Min EPS beat(4)-22.4%
Max EPS beat(4)-4.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.97%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)2.67%
Revenue beat(4)2
Avg Revenue beat(4)0.69%
Min Revenue beat(4)-4.07%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.26%
PT rev (3m)0.15%
EPS NQ rev (1m)-13.25%
EPS NQ rev (3m)-10.74%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-4.15%
Revenue NQ rev (3m)-3.54%
Revenue NY rev (1m)-0.69%
Revenue NY rev (3m)-0.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.8 | ||
| Fwd PE | 27.97 | ||
| P/S | 3.83 | ||
| P/FCF | 23.1 | ||
| P/OCF | 14.47 | ||
| P/B | 5 | ||
| P/tB | N/A | ||
| EV/EBITDA | 19.99 |
EPS(TTM)4.35
EY2.45%
EPS(NY)6.35
Fwd EY3.57%
FCF(TTM)7.68
FCFY4.33%
OCF(TTM)12.27
OCFY6.91%
SpS46.31
BVpS35.5
TBVpS-35.06
PEG (NY)1.78
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.04% | ||
| ROE | 3.92% | ||
| ROCE | 5.11% | ||
| ROIC | 3.8% | ||
| ROICexc | 4.21% | ||
| ROICexgc | 13.6% | ||
| OM | 12.48% | ||
| PM (TTM) | 3% | ||
| GM | 45.76% | ||
| FCFM | 16.59% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexcg growth 3Y-35.26%
ROICexcg growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.54 | ||
| Debt/FCF | 8.09 | ||
| Debt/EBITDA | 4.76 | ||
| Cap/Depr | 80.56% | ||
| Cap/Sales | 9.91% | ||
| Interest Coverage | 2.25 | ||
| Cash Conversion | 106.92% | ||
| Profit Quality | 552.64% | ||
| Current Ratio | 1.39 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 1.99 |
F-Score7
WACC6.93%
ROIC/WACC0.55
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)33.21%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%7.02%
EPS Next Y22.89%
EPS Next 2Y24.43%
EPS Next 3Y26.21%
EPS Next 5Y19.27%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%2.74%
Revenue Next Year5.64%
Revenue Next 2Y7.36%
Revenue Next 3Y8.73%
Revenue Next 5Y8.5%
EBIT growth 1Y1.03%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year103.14%
EBIT Next 3Y38.58%
EBIT Next 5Y26.99%
FCF growth 1Y187.94%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y14.51%
OCF growth 3Y4.07%
OCF growth 5Y20.79%